文章摘要
黄 莉,鲁利群,汪 燕,吕 洁,刘明全.布地奈德联合孟鲁司特钠治疗哮喘儿童的临床效果及对患儿免疫功能、CysLTs及FLAP表达的影响[J].,2019,19(3):544-547
布地奈德联合孟鲁司特钠治疗哮喘儿童的临床效果及对患儿免疫功能、CysLTs及FLAP表达的影响
Clinical Efficacy of Budesonide combined with Montelukast Sodium in the Treatment of Children with Asthma and Its Effect on the Immunefunction, Serum CysLTs and FLAP Levels
投稿时间:2018-06-07  修订日期:2018-06-30
DOI:10.13241/j.cnki.pmb.2019.03.034
中文关键词: 布地奈德  孟鲁司特钠  支气管哮喘  免疫功能  半胱氨酸白三烯  5-脂氧合酶激活蛋白
英文关键词: Budesonide  Montelukast sodium  Bronchial asthma  Immune function  Cysteine leukotriene  Five lipoxygenase activating protein
基金项目:
作者单位E-mail
黄 莉 成都医学院第一附属医院儿科 四川 成都 610500 huangli569@163.com 
鲁利群 成都医学院第一附属医院儿科 四川 成都 610500  
汪 燕 成都医学院第一附属医院儿科 四川 成都 610500  
吕 洁 成都医学院第一附属医院儿科 四川 成都 610500  
刘明全 成都医学院第一附属医院检验科 四川 成都 610500  
摘要点击次数: 89
全文下载次数: 108
中文摘要:
      摘要 目的:探讨布地奈德联合孟鲁司特钠治疗哮喘儿童的临床效果及对患儿免疫功能、血清半胱氨酸白三烯(CysLTs)及5-脂氧合酶激活蛋白(FLAP)表达的影响。方法:选取2015年3月至2017年1月我院收治的支气管哮喘患儿118例,按随机原则将其分为对照组和观察组,每组各59例。对照组通过布地奈德气雾剂进行治疗,观察组在对照组的基础上联用孟鲁司特钠进行治疗,分析和比较两组的临床疗效、治疗前后肺功能、免疫功能、血清CysLTs及FLAP水平的变化。结果:治疗后,观察组临床总有效率(93.22%)显著高于对照组(77.97%)(P<0.05);两组FEV1、FVC及FEV1/FVC均较治疗前显著增加(P<0.05),且观察组FEV1、FVC及FEV1/FVC较对照组显著增加(P<0.05);两组CD4+及CD4+/CD8+较治疗前显著增加,CD8+较治疗前显著降低(P<0.05),观察组CD4+及CD4+/CD8+较对照组显著增加,CD8+较对照组显著降低(P<0.05);两组CysLTs及FLAP较治疗前显著降低(P<0.05),观察组CysLTs及FLAP较对照组显著降低(P<0.05)。结论:布地奈德与孟鲁司特钠联合用药能有效的提高哮喘患儿的临床疗效,改善患儿肺功能,其作用机制可能与增强患儿免疫功能及降低血清CysLTs及FLAP的表达有关。
英文摘要:
      ABSTRACT Objective: To explore the clinical effect of budesonide combined with montelukast sodium in the treatment of children with asthma and it's effect on the immune function, serum cysteine leukotriene (CysLTs) and the expression of 5- lipoxygenase activator protein (FLAP). Methods: 118 cases of bronchial asthma were selected in our hospital from March 2015 to January 2017, and divided them into control group and observation group according to the principle of randomization, with 59 cases in each group. The control group was treated with Budesonide Aerosol, and the observation group was treated with montelukast sodium on the basis of the control group. The clinical effect and the changes of lung function, immune index, CysLTs, FLAP level and clinical effect between the two groups before and after treatment were compared and analyzed. Results: After treatment, the total effective rate of the observation group (93.22%) was significantly higher than that of the control group (77.97%) (P<0.05); the index of FEV1, FVC and FEV1/FVC in two groups increased significantly compared with those before treatment (P<0.05), and the index of FEV1, FVC and FEV1/FVC in the observation group were significantly higher than those in the control group (P<0.05); the CD4+ and CD4+/CD8+ of two groups were significantly increased before treatment, and CD8+ was significantly lower than before treatment (P<0.05), the CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the CD8+ was significantly lower than the control group (P<0.05); the two groups of CysLTs and FLAP were significantly lower than those before treatment (P<0.05), and the CysLTs and FLAP in the observation group were significantly lower than those in the control group (P<0.05). Conclusions: The combination of budesonide and montelukast can effectively improve the clinical efficacy and improve the pulmonary function of children with asthma. The mechanism may be related to the enhancement of immune function and the reduction of the expression of serum CysLTs and FLAP.
查看全文   查看/发表评论  下载PDF阅读器
关闭